QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.

Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

No news is good news for this medical device company.

Why Quidel Corporation Stock Rose Today

Is (QDEL) Outperforming Other Medical Stocks This Year?

Is Quidel (QDEL) Stock Outpacing Its Medical Peers This Year?

Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quidel (QDEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

SAN DIEGO--(BUSINESS WIRE)-- #FightLyme--Quidel Corporation announced it will be one of the sponsors of the inaugural Global Lyme Alliance “Fight Lyme With Avril Lavigne and Friends" concert.

Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne and Friends' Virtual Concert Oct. 24

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report third fiscal quarter 2020 financial results after market close on Thursday, October 29, 2020. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern T

Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020

PayPal

Shopify

These stay-at-home stocks are most likely to capitalize on an uptick in online traffic during a second wave of the novel coronavirus. The post 3 Stay-at-Home Stocks to Buy if a Second Wave Hits appeared first on InvestorPlace.

3 Stay-at-Home Stocks to Buy if a Second Wave Hits

OPKO Health

Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.

Quidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?

Ampco-Pittsburgh

Group 1 Automotive

Worthington Industries

Top Ranked Momentum Stocks to Buy for October 16th

Abbott Labs

Quest Diagnostics

Hologic

Labcorp Holdings Inc

Our indicative theme of Covid-19 Testing Stocks, which includes medical devices and diagnostic companies that are involved in Covid-19 testing - is up by about 69% year-to-date, significantly outperforming the S&P 500 which is up by about 8% over the same period. Testing is viewed as key to.

Covid Testing Stocks To Watch As The Holidays Near

Salesforce

Etsy

Goosehead Insurance

Simulations Plus

Stamps.com

United Microelectronics

There’s a difference between high-priced and expensive, and some of the best growth stocks to buy under $1,000 come with big price tags. The post The 7 Best Growth Stocks To Buy For Less Than$1000 appeared first on InvestorPlace.

The 7 Best Growth Stocks To Buy For Less Than$1000

Alteryx

NVIDIA

Two women will share the Nobel prize for a gene editing technology that will change the world.

Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

Teams from the Pac-10 and Big 10 conferences are returning to action safely, thanks in great part to Quidel Corp. (NASDAQ:QDEL). Student athletes and staff personnel from member schools will be checked before every practice and every game for Covid-19 using the San Diego-based company's diagnostic test.

Analysts Set Quidel Median Target Price Above $360

Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Quidel (QDEL)

Becton, Dickinson and Co.

Fluidigm

Eli Lilly

Luminex

PerkinElmer

QIAGEN

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia® 2 Flu + SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia® 2 Fluorescent Immunoassay Analyzer for the rapid, simultaneous qualitative detection

Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19

Albertsons Companies

Ardagh Group

Berry Global Group

Brighthouse Financial

Brookfield Property REIT

Immunomedics

Livongo Health Inc

Moderna

NortonLifeLock

NRG Energy

Tesla

Zoom Video

These are the stocks with the best value, fastest growth, and most momentum for October 2020.

Top Stocks for October 2020

Exact Sciences

Guardant Health Inc

Illumina

Natera

Invitae

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

7 Diagnostic and Genomic Stocks Storming Into October

The company gave investors a sneak peek into its upcoming quarterly update.

Why Quidel Stock Is Up Today

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the third fiscal quarter of 2020 to be in the range of $475 million to $477 million. "The entire team at Quidel has truly risen to the challenge of the COVID-19 pandemic, producing and shipping millions of tests to those with the greatest need, and further democrati

Quidel Announces Preliminary Revenue for Third Quarter 2020

Biogen

Bio-Rad Laboratories

CVS Health

Insulet

Perrigo

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Top Healthcare Stocks for October 2020

Quidel (QDEL) closed at $196.21 in the latest trading session, marking a -1.39% move from the prior day.

Quidel (QDEL) Stock Moves -1.39%: What You Should Know

Quidel has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Quidel Enters Oversold Territory

Thermo Fisher Scientific

The surge in new coronavirus infections  broadens the scope for antigen and antibody tests.

Coronavirus Test Makers With Scope to Maximize Investor Benefits

News for QuidelOrtho Corp Stock (QDEL)